We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Innate Pharma | EU:IPH | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.07 | 3.21% | 2.25 | 2.235 | 2.255 | 2.26 | 2.20 | 2.23 | 53,183 | 15:49:32 |
By Colin Kellaher
Shares of Innate Pharma SA tumbled sharply on Monday following the failure of the clinical-stage biotech company's lead partnered asset in a Phase 3 study in head and neck cancer.
The Marseille, France, company said the study evaluating monalizumab in combination with cetuximab versus cetuximab alone in patients with recurrent or metastatic squamous cell carcinoma of the head and neck didn't meet a pre-defined threshold for efficacy, and that partner AstraZeneca PLC was pulling the plug on the trial.
Innate, which has licensed full oncology rights to monalizumab to AstraZeneca under a 2015 development and commercialization agreement, said it remains confident in the development program for monalizumab in lung cancer.
Paris-listed shares of Innate were recently down 16% to EUR2.53, while its U.S.-listed shares fell 17% in premarket trading to $2.66.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 01, 2022 06:15 ET (10:15 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Innate Pharma Chart |
1 Month Innate Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions